An Upgrade on the Rabbit Model of Anthracycline-Induced Cardiomyopathy: Shorter Protocol, Reduced Mortality, and Higher Incidence of Overt Dilated Cardiomyopathy

BioMed Research International
Jesús TalaveraJose M Moraleda

Abstract

Current protocols of anthracycline-induced cardiomyopathy in rabbits present with high premature mortality and nephrotoxicity, thus rendering them unsuitable for studies requiring long-term functional evaluation of myocardial function (e.g., stem cell therapy). We compared two previously described protocols to an in-house developed protocol in three groups: Group DOX2 received doxorubicin 2 mg/kg/week (8 weeks); Group DAU3 received daunorubicin 3 mg/kg/week (10 weeks); and Group DAU4 received daunorubicin 4 mg/kg/week (6 weeks). A cohort of rabbits received saline (control). Results of blood tests, cardiac troponin I, echocardiography, and histopathology were analysed. Whilst DOX2 and DAU3 rabbits showed high premature mortality (50% and 33%, resp.), DAU4 rabbits showed 7.6% premature mortality. None of DOX2 rabbits developed overt dilated cardiomyopathy; 66% of DAU3 rabbits developed overt dilated cardiomyopathy and quickly progressed to severe congestive heart failure. Interestingly, 92% of DAU4 rabbits showed overt dilated cardiomyopathy and 67% developed congestive heart failure exhibiting stable disease. DOX2 and DAU3 rabbits showed alterations of renal function, with DAU3 also exhibiting hepatic function compromise. Thus,...Continue Reading

References

Apr 1, 1987·American Journal of Clinical Oncology·S L CurryJ Arseneau
Sep 24, 1998·The New England Journal of Medicine·P K Singal, N Iliskovic
Jan 24, 2003·Human & Experimental Toxicology·Ivona KlimtováMichaela Adamcová
May 15, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·O HequetB Coiffier
Jun 9, 2004·European Journal of Heart Failure·Tomás SimůnekVladimír Gersl
Jun 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joseph R CarverUNKNOWN ASCO Cancer Survivorship Expert Panel
Aug 24, 2007·The Lancet Oncology·Arduino VerdecchiaUNKNOWN EUROCARE-4 Working Group
Apr 25, 2008·The Journal of Pharmacology and Experimental Therapeutics·Olga PopelováVladimír Gersl
Jul 17, 2008·The Canadian Journal of Cardiology·Peter P Liu
Aug 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Luca GianniDouglas B Sawyer
Feb 3, 2011·Journal of Molecular and Cellular Cardiology·Martin StěrbaVladimír Geršl
Nov 30, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Javier G BlancoSmita Bhatia
Feb 22, 2012·Anti-cancer Drugs·Megan M FreelandLisa E Olson
Aug 21, 2012·Research in Veterinary Science·Fábio N GavaAparecido A Camacho
Oct 1, 2013·The American Journal of Cardiology·Marzia LotrionteGiovanni Palazzoni
Aug 26, 2014·Journal of Pharmacy Practice·Jason N BarretoJudith A Smith
Nov 26, 2014·Circulation. Heart Failure·Maryline MoulinRenée Ventura-Clapier
Oct 1, 2008·Drug Discovery Today. Disease Models·Steven M Pogwizd, Donald M Bers

❮ Previous
Next ❯

Citations

Feb 6, 2017·Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Für Toxikologische Pathologie·João Lucas O'ConnellMarcus V Simões
May 22, 2020·Environmental Science and Pollution Research International·Shaukat AliMuhammad Adeeb Khan
Mar 30, 2021·Research in Veterinary Science·Mitsuhiro IsakaRyuji Araki

❮ Previous
Next ❯

Software Mentioned

GraphPad Prism
SPSS Statistics

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.